Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Aurobindo Pharma
  6. News
  7. Summary
    AUROPHARMA   INE406A01037

AUROBINDO PHARMA

(AUROPHARMA)
  Report
Delayed NSE India Stock Exchange  -  06:23:12 2023-02-03 am EST
404.20 INR   -1.43%
02/03Aurobindo Pharma : Q3fy23
PU
01/18Indian shares seen opening lower on U.S. recession fears, hawkish Fed
RE
01/18Aurobindo Pharma Gets Two Observations from US FDA After Inspection of Unit's Facility in Telangana, India
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome

11/18/2022 | 12:26am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -0.55% 1889.5 Delayed Quote.-5.83%
AUROBINDO PHARMA -1.43% 404.2 Delayed Quote.-7.78%
MSCI TAIWAN (STRD) 0.01% 587.501 Real-time Quote.16.71%
TTY BIOPHARM COMPANY LIMITED -0.26% 77.4 End-of-day quote.-7.19%
All news about AUROBINDO PHARMA
02/03Aurobindo Pharma : Q3fy23
PU
01/18Indian shares seen opening lower on U.S. recession fears, hawkish Fed
RE
01/18Aurobindo Pharma Gets Two Observations from US FDA After Inspection of Unit's Facility ..
MT
01/11Aurobindo Receives FDA Approval for Emzahh 0.35mg
AQ
01/04Aurobindo Pharma Arm Gets US FDA Nod for Azacitidine for Injection
MT
2022Aurobindo Pharma Unit Gets Marketing Nod in India for Pneumococcal Vaccine
MT
2022Aurobindo Receives FDA Approval for Ursodiol Capsules USP, 300mg
AQ
2022Aurobindo Receives FDA Approval for Carbidopa and Levodopa Tablets
AQ
2022Aurobindo Pharma Unit Ties Up with Evive to Commercialize Ryzneuta in US
MT
2022Aurobindo Pharma Plans to Complete New Penicillin Unit by March 2024
MT
More news
Financials
Sales 2023 244 B 2 970 M 2 970 M
Net income 2023 21 405 M 260 M 260 M
Net cash 2023 21 601 M 263 M 263 M
P/E ratio 2023 11,1x
Yield 2023 0,98%
Capitalization 237 B 2 879 M 2 879 M
EV / Sales 2023 0,88x
EV / Sales 2024 0,78x
Nbr of Employees 15 431
Free-Float 47,9%
Chart AUROBINDO PHARMA
Duration : Period :
Aurobindo Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUROBINDO PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 404,20 INR
Average target price 574,35 INR
Spread / Average Target 42,1%
EPS Revisions
Managers and Directors
Kambam Nithyananda Reddy Vice Chairman & Managing Director
Santhanam Subramanian Chief Financial Officer
Kannan Ragunathan Non-Executive Chairman
B. Adi Reddy Secretary & Compliance Officer
Avnit Bimal Singh Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AUROBINDO PHARMA-7.78%2 879
JOHNSON & JOHNSON-6.29%430 370
ELI LILLY AND COMPANY-9.61%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994